This study involves patients who have experienced acute ischemic stroke, which is a condition where a blood clot blocks a blood vessel in the brain, cutting off the blood supply and potentially causing brain damage. The blockage occurs specifically in the front part of the brain’s blood circulation system. The study will test a medication called Tenecteplase, which is a clot-dissolving drug, and compare it to placebo. The medication will be given directly into the affected blood vessel in the brain after a procedure has been performed to remove the clot mechanically using special instruments inserted through the blood vessels.
The purpose of this study is to find out whether giving Tenecteplase directly into the brain’s blood vessel after successful removal of the clot leads to better recovery compared to not giving this additional treatment. The study will measure success by looking at how well patients can function in their daily lives three months after the stroke, specifically checking if they have little to no disability. During the study, patients will first undergo a procedure to remove the blood clot from their brain using mechanical methods. If this procedure successfully reopens the blocked blood vessel, patients will then receive either the clot-dissolving medication or placebo injected directly into the artery in the brain.
The study will follow patients for 90 days after treatment to assess their recovery and ability to perform daily activities. The treatment must be given within 24 hours from when the stroke symptoms began or from when the patient was last known to be well. Patients enrolled in this study will have experienced a stroke caused by a blockage in one of the major blood vessels supplying the front part of the brain, and they must have had successful reopening of this vessel during the mechanical clot removal procedure.
Germany 
